JP2013540421A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540421A5
JP2013540421A5 JP2013518914A JP2013518914A JP2013540421A5 JP 2013540421 A5 JP2013540421 A5 JP 2013540421A5 JP 2013518914 A JP2013518914 A JP 2013518914A JP 2013518914 A JP2013518914 A JP 2013518914A JP 2013540421 A5 JP2013540421 A5 JP 2013540421A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
cancer
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518914A
Other languages
English (en)
Japanese (ja)
Other versions
JP5964298B2 (ja
JP2013540421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2011/000823 external-priority patent/WO2012006727A1/en
Publication of JP2013540421A publication Critical patent/JP2013540421A/ja
Publication of JP2013540421A5 publication Critical patent/JP2013540421A5/ja
Application granted granted Critical
Publication of JP5964298B2 publication Critical patent/JP5964298B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518914A 2010-07-15 2011-07-15 ヒトパピローマウイルスe7抗原組成物およびその使用 Expired - Fee Related JP5964298B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36475010P 2010-07-15 2010-07-15
US61/364,750 2010-07-15
PCT/CA2011/000823 WO2012006727A1 (en) 2010-07-15 2011-07-15 Human papillomavirus e7 antigen compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2013540421A JP2013540421A (ja) 2013-11-07
JP2013540421A5 true JP2013540421A5 (https=) 2014-08-28
JP5964298B2 JP5964298B2 (ja) 2016-08-03

Family

ID=45468847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518914A Expired - Fee Related JP5964298B2 (ja) 2010-07-15 2011-07-15 ヒトパピローマウイルスe7抗原組成物およびその使用

Country Status (12)

Country Link
US (1) US20130209402A1 (https=)
EP (1) EP2593548A4 (https=)
JP (1) JP5964298B2 (https=)
KR (1) KR20130142104A (https=)
CN (1) CN103119168A (https=)
AU (1) AU2011279365A1 (https=)
BR (1) BR112013000912A2 (https=)
CA (1) CA2805300A1 (https=)
MX (1) MX2013000584A (https=)
NZ (1) NZ606949A (https=)
RU (1) RU2013106498A (https=)
WO (1) WO2012006727A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107868127A (zh) * 2016-09-28 2018-04-03 艾托金生物医药(苏州)有限公司 一种用于检测病理组织切片中癌蛋白表达的单克隆抗体
CN109384848A (zh) * 2017-08-10 2019-02-26 深圳市雅臣智能生物工程有限公司 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
AU2007241406A1 (en) * 2006-04-21 2007-11-01 Transgene S.A. HPV-16-based papillomavirus vaccine
US20110142873A1 (en) * 2006-05-31 2011-06-16 Gerry Rowse Bioactive purified hspe7 compositions

Similar Documents

Publication Publication Date Title
Zhai et al. Gardasil-9: A global survey of projected efficacy
Kim et al. Current status and future prospects for human papillomavirus vaccines
CN100532548C (zh) 一种提高人乳头瘤病毒l1蛋白原核表达产率的方法
Stanley Prophylactic HPV vaccines
WO2002090382A3 (fr) Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA2543928A1 (en) Optimized expression of hpv 58 l1 in yeast
CA2539168A1 (en) Optimized expression of hpv 45 l1 in yeast
WO2008098484A1 (en) Recombinant l1 proteins of human papilloma virus and uses thereof
EP2155240B1 (en) Intradermal hpv peptide vaccination
JP2015508284A5 (https=)
RU2005132603A (ru) Оптимизированная экспрессия hpv 31 l1 в дрожжах
Oumeslakht et al. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency
CN112618713A (zh) 抗hpv及抗妇科炎症复合卵黄球蛋白组合物及凝胶剂
JP2013540421A5 (https=)
Ahmed et al. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines
RU2013106498A (ru) Антигенные композиции папилломавируса человека е7 и их применение
Webb et al. Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein
CN114716560B (zh) 一种人乳头瘤病毒18型嵌合蛋白及其用途
Guo et al. Development Status and trend of HPV vaccine
Xie et al. Prevalence and genotype distribution of human papillomavirus in Yueyang city from 2019 to 2022
Wang et al. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques
Uslimgazieva et al. HUMAN PAPILLOMA VIRUS AND HUMAN PAPILLOMA VIRUS VACCINES
Ислямгазиева et al. Uslimgazieva Sholpan, N. Kolokolova
Munteanu HUMAN PAPILLOMAVIRUS (HPV): VACCINATION AND EVOLUTION OF CIRCULATING GENOTYPES IN THE POST-VACCINE ERA
TH108752A (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์